Experts have theorized that mucosal vaccines, which could be administered nasally, orally or transdermally, could alter the trajectory of the pandemic. But a recent setback involving an intranasal version of AstraZeneca’s ChAdOx1 nCoV-19 COVID-19 has dampened those hopes.  A Phase 1 study published on Lancet’s eBioMedicine found that intranasal vaccination was detectable in a minority of participants.…

AstraZeneca (LON:AZN) and the European Union have agreed to end litigation related to the supply of its COVID-19 vaccine Vaxzevria (ChAdOx1-S). AstraZeneca had initially contracted with the European Commission to provide 300 million doses of its vaccine with an option for another 100 million, but fell short of its commitment. The level of vaccine doses,…